SCIE 1P51 Lecture Notes - Lecture 11: Clinical Trial, Median Toxic Dose, Blind Experiment
15 Apr 2013
School
Department
Course
Professor
Document Summary
Must be tested and evaluated toxicologically in all aspects. Autogenetic 2+ 2 = 3 (reduces efficacy) Very few breakthrough treatments for chronic diseases. Makes inferences to population who require treatment in the future. A prospective study comparing the effect and value of interventions against a control in human subjects. Typical time from synthesis to battle: 12 years. Phase 1 testing (most clinical trials pay subjects, depending on the treatment) Healthy subjects or may include subjects with known conditions. Interaction studies food, other meds: 1 year, 5 compounds enter trial. Study of absorption, distribution, metabolism, and elimination of drugs (adme) Physicians may be asked/paid by drug company for access to effects and acceptance of drug by patient. Control group study: treatment absent, no active ingredient. Patient does not know if the control group or treatment group. Neither patient nor-researcher knows who is in the control group or treatment group. Positive control (test new against old) (no placebo)
